Our newest product candidate SRF813 targets the checkpoint protein CD112R to promote NK and T cell activation: potentially overcoming checkpoint inhibitor resistance. Our preclinical data supports differentiated activity and induction of immune memory.
https://t.co/3BqZsE5hAs